Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (FY)Mar 31, 2025 | (Q4)Mar 31, 2025 | (Q3)Dec 31, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (FY)Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|
| Total revenue | -52.73%714.94B | -49.19%198.02B | -47.85%179.91B | -7.70%1.51T | 389.72B | 345.02B | 1.64T |
| Cost of revenue | -58.33%557.98B | -56.67%154.36B | -54.38%141.33B | -4.08%1.34T | 356.26B | 309.78B | 1.4T |
| Gross profit | -9.48%156.96B | 30.48%43.66B | 9.48%38.58B | -28.51%173.4B | 33.46B | 35.24B | 242.57B |
| Operating expense | -25.93%105.44B | -19.70%38.12B | -24.61%31.15B | -32.85%142.34B | 47.48B | 41.31B | 211.98B |
| Selling and administrative expenses | -4.97%100.16B | 13.42%29.4B | 3.33%24.26B | -14.18%105.39B | --25.92B | --23.47B | --122.81B |
| -General and administrative expense | -4.97%100.16B | 13.42%29.4B | 3.33%24.26B | -14.18%105.39B | --25.92B | --23.47B | --122.81B |
| Other operating expenses | -65.45%22.37B | -58.55%9.34B | -54.41%7.66B | -31.84%64.73B | --22.52B | --16.8B | --94.98B |
| Total other operating income | -38.51%17.08B | -36.45%612M | 173.72%766M | 378.69%27.78B | --963M | ---1.04B | --5.8B |
| Operating profit | 65.88%51.53B | 139.50%5.54B | 222.30%7.43B | 1.53%31.06B | -14.02B | -6.08B | 30.59B |
| Net non-operating interest income (expenses) | 32.85%-5.01B | 27.96%-1.76B | -48.91%-1.1B | 22.30%-7.46B | -2.44B | -736M | -9.6B |
| Non-operating interest income | -23.22%2.41B | -3.57%703M | -18.65%641M | 50.14%3.14B | --729M | --788M | --2.09B |
| Non-operating interest expense | -30.00%7.42B | -22.35%2.46B | 13.98%1.74B | -9.35%10.59B | --3.17B | --1.52B | --11.69B |
| Net investment income | |||||||
| Gain(Loss) on financial instruments designated as cash flow hedges | |||||||
| Gain(Loss) on derecognition of available-for-sale financial assets | |||||||
| Income from associates and other participating interests | 10.61%60.96B | 21.94%20.78B | -31.09%10.62B | 30.19%55.11B | 17.04B | 15.41B | 42.33B |
| Special income (charges) | 10.61%60.96B | 21.94%20.78B | -31.09%10.62B | 30.19%55.11B | 17.04B | 15.41B | 42.33B |
| Less:Other special charges | -10.61%-60.96B | -21.94%-20.78B | 31.09%-10.62B | -30.19%-55.11B | ---17.04B | ---15.41B | ---42.33B |
| Other non-operating income (expenses) | 85.71%-5.28B | 59.53%-8.72B | 61.36%-6.89B | 58.56%-36.95B | -21.56B | -17.84B | -89.17B |
| Income before tax | 36.54%107.48B | 4,148.10%24.55B | 97.16%16.95B | 24.30%78.71B | 578M | 8.6B | 63.33B |
| Income tax | 172.12%26.09B | 95.14%-2.98B | -13.24%7.27B | -377.81%-36.17B | -61.25B | 8.38B | 13.02B |
| Net income | -29.16%81.39B | -55.47%27.53B | 4,225.00%9.69B | 128.38%114.89B | 61.83B | 224M | 50.31B |
| Net income continuous operations | -29.16%81.39B | -55.47%27.53B | 4,225.00%9.69B | 128.38%114.89B | --61.83B | --224M | --50.31B |
| Noncontrolling interests | 6.96%13.12B | 499.21%5.29B | -92.57%389M | -8.32%12.26B | 883M | 5.23B | 13.38B |
| Net income attributable to the company | -33.47%68.27B | -63.51%22.24B | 285.61%9.3B | 177.89%102.62B | 60.95B | -5.01B | 36.93B |
| Preferred stock dividends | |||||||
| Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income attributable to common stockholders | -33.47%68.27B | -63.51%22.24B | 285.61%9.3B | 177.89%102.62B | 60.95B | -5.01B | 36.93B |
| Gross dividend payment | |||||||
| Basic earnings per share | -33.48%73.53 | -63.51%23.9557 | 285.61%10.0155 | 177.89%110.5311 | 65.645 | -5.396 | 39.7754 |
| Diluted earnings per share | -33.48%73.53 | -63.51%23.9557 | 285.61%10.0155 | 177.89%110.5311 | 65.645 | -5.396 | 39.7754 |
| Dividend per share | 18 | 18 | |||||
| Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
| Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |